Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.69)
# 3,097
Out of 4,711 analysts
40
Total ratings
41.03%
Success rate
-3.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $70.44 | - | 6 | Jun 20, 2024 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.72 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $7.10 | - | 6 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $64.12 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $1.20 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $0.76 | - | 3 | May 15, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Overweight | $14 | $9.45 | +48.15% | 2 | Oct 10, 2023 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.77 | +158.30% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $3.75 | +273.33% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $4.87 | +577.62% | 2 | Jul 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.63 | +71.10% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.38 | +7,146.38% | 2 | May 17, 2022 |
Insmed
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.44
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.72
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.10
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.12
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.76
Upside: -
Poseida Therapeutics
Oct 10, 2023
Reiterates: Overweight
Price Target: $14
Current: $9.45
Upside: +48.15%
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.77
Upside: +158.30%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $3.75
Upside: +273.33%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $4.87
Upside: +577.62%
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.63
Upside: +71.10%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.38
Upside: +7,146.38%